XFOR News & Events

X4 Pharmaceuticals files $300M mixed securities shelf

Reports Q1 revenue $2.71M, consensus $3.2M. "Our top priority remains the execution and full enrollment of the pivotal 4WARD Phase 3 trial of mavorixafor in chronic neutropenia," said Adam Craig, Executive Chairman of X4 Pharmaceuticals. "We remain on track to complete enrollment by the end of the third quarter of this year. In addition, we are pleased that the European Commission granted marketing authorization for XOLREMDI for the treatment of patients with WHIM syndrome in the European Union, reinforcing the broader potential of our program to advance therapies for individuals affected by rare hematologic disorders. We look forward to a smooth transfer of the marketing authorization application to our European partner, Norgine, later this year as they proceed with commercialization plans throughout Europe."

X4 Pharmaceuticals announced that the European Commission has granted marketing authorization for Xolremdi capsules for the treatment of patients with WHIM syndrome in the European Union. "The approval of mavorixafor in the European Union marks an important step in extending access to XOLREMDI beyond the United States and providing a new, targeted therapeutic option to patients living with WHIM syndrome, an ultra-rare hematologic disorder," said Adam Craig, executive chairman of X4 Pharmaceuticals. "We look forward to working with Norgine, our commercial partner in Europe, to enable patient access to mavorixafor to treat this devastating condition. In addition, we are now running a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenia to further explore its potential benefit across multiple diseases."

Cash, cash equivalents and short-term investments totaled $253.0 million as of December 31, 2025, which management believes will enable the Company to fund its operations through 2028.